The Joint Corp. Reports Third Quarter 2026 Financial Results

Lower sales expectations accompany higher continuing-operations profit and an additional $5 million share repurchase authorization.

Rhea-AI Summary

The Joint (NASDAQ: JYNT) reported third-quarter revenue of $13.6 million, up 1% from the same period last year. Continuing-operations net income rose to $1.5 million from $290,000, while consolidated results swung to a $117,000 loss from $855,000 income. System-wide sales fell 3.1% to $123.3 million; comparable-clinic sales fell 1.9%, versus 2.8% in the second quarter.

The company lowered 2026 system-wide sales guidance to $508 million–$512 million from $519 million–$552 million, while maintaining consolidated adjusted EBITDA guidance of $12.5 million–$13.5 million. Operating cash use was $128,000, versus $1.8 million generated a year earlier. Third-quarter share repurchases totaled approximately $3.8 million, and the board authorized another $5 million. On October 1, Texas regional developer rights were reacquired for $8 million at closing plus up to $2 million contingent on sales metrics.

18 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointContinuing-operations net income rose to $1.5 million from $290,000 in third-quarter 2025.
• Moderate pointContinuing-operations adjusted EBITDA, a non-GAAP earnings measure, rose to $2.3 million from $1.4 million year over year.
• Moderate pointThird-quarter repurchases totaled approximately 461,000 shares for approximately $3.8 million, averaging $8.30 per share. 3.6% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Additional $5 million repurchase authorization was approved by the board on November 3, 2026. 4.7% of market cap
• Moderate pointTexas regional developer rights were reacquired October 1, covering 141 franchised clinics.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Five territory rights reacquisitions covering 189 franchised clinics are expected to reduce annualized royalties approximately $3.0 million.
• Moderate pointNine-month revenue increased 10% to $43.6 million from $39.7 million a year earlier.
• Moderate pointNine-month continuing-operations income reached $2.3 million, versus a $1.2 million loss a year earlier.
• Moderate pointNine-month continuing-operations adjusted EBITDA increased to $5.9 million from $1.5 million a year earlier.
• Moderate pointUndrawn credit line provides access to $20 million through August 2029. 19% of market cap

8 minor points

• Minor pointThird-quarter revenue rose 1% year over year to $13.6 million.
• Minor pointCost of revenues fell 10% year over year to $2.4 million in the third quarter.
• Minor pointGeneral and administrative expenses decreased 6% to $6.9 million from $7.3 million a year earlier.
• Minor pointSelling and marketing expenses decreased 4% year over year to $2.7 million.
• Minor pointRefranchising progressed with 26 clinics refranchised during the third quarter.
• Minor pointNine-month diluted EPS increased to $0.13 from $0.12 a year earlier.
• Minor pointNine-month consolidated adjusted EBITDA increased to $9.9 million from $9.4 million a year earlier.
• Minor pointActive membership and lifetime value per active member grew in the third quarter.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.2026 system-wide sales guidance lowered to $508 million–$512 million from $519 million–$552 million.
• Moderate pointThird-quarter system-wide sales fell 3.1% year over year to $123.3 million.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Texas rights consideration included $8.0 million cash due at closing and up to $2.0 million contingent payments. 7.5% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Year-end clinic count is expected approximately 50 below 2025 year-end, including closures of underperforming clinics.
• Minor point. Forward-looking: it has not happened yet and may not happen.2026 comparable-sales guidance lowered to negative 3.5%–negative 2.5%, from negative 3%–positive 3%.

9 minor points

• Minor pointComparable-clinic sales fell 1.9%, versus a 2.8% decline in second-quarter 2026.
• Minor pointConsolidated quarterly loss was $117,000, versus $855,000 income; EPS was negative $0.01 versus diluted $0.06.
• Minor pointOperating cash flow used $128,000, versus $1.8 million generated in third-quarter 2025.
• Minor pointFree cash flow was negative $509,000, versus positive $1.5 million in third-quarter 2025.
• Minor pointUnrestricted cash fell to $18.3 million at September 30 from $22.2 million at June 30, 2026.
• Minor point. Forward-looking: it has not happened yet and may not happen.Internal territory-management costs are expected to offset approximately one-third of the approximately $3.0 million annualized royalty savings.
• Minor pointClinic closures totaled 15 in the quarter, compared with four openings.
• Minor pointNine-month consolidated net income declined to $1.8 million from $1.9 million a year earlier.
• Minor pointLower monthly patient spending and fewer new patients partially offset membership-related growth.

News Explained

The additional $5 million authorization approved November 3, 2026 is capacity, not a committed purchase: after exhausting the prior $12 million authorization by September 30, 2026, the company says it is not obligated to buy any particular amount, and timing and size remain with management and the board.

Argus 15 min delay 3 alerts

-7.73% vs previous close $6.80 last price 1.4x rel. volume Open Argus

Details

Market move: JYNT -7.73% vs previous close. 3Q26 earnings report

$6.80 – $7.74 Day Range

$96.17M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for JYNT is 7.73% below the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $6.80.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Revenue: $13.6 million, up 1% System-wide sales: $123.3 million, down 3.1% Net income from continuing operations: $1.5 million, versus $290,000 +5 more

Revenue

$13.6 million, up 1%

Q3 2026 year over year

System-wide sales

$123.3 million, down 3.1%

Q3 2026 year over year

Net income from continuing operations

$1.5 million, versus $290,000

Q3 2026 versus Q3 2025

Adjusted EBITDA from continuing operations

$2.3 million, versus $1.4 million

Q3 2026 versus Q3 2025

Operating cash flow

$128,000 used, versus $1.8 million provided

Q3 2026 versus Q3 2025

Additional stock repurchase authorization

$5.0 million

Authorized by the board on November 3, 2026

System-wide sales guidance

$508 million–$512 million (prior: $519 million–$552 million)

Updated FY2026 guidance

System-wide comp sales guidance

(3.5)%–(2.5)% (prior: (3)%–3%

Updated FY2026 guidance for clinics open 13 months or more

Previous Earnings Reports

1 past event · Latest: Aug 06

Same Type 1 event

1. Aug 06

   Q2 earnings

   24h Move

   +1.3%

   Continuing-operations EBITDA increased and comp sales improved sequentially.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adjusted ebitda, non-gaap, free cash flow

3 terms

adjusted ebitda financial

"Adjusted EBITDA (a non-GAAP metric) from consolidated operations"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

non-gaap financial

"Adjusted EBITDA (a non-GAAP metric) from consolidated operations"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

free cash flow financial

"free cash flow (a non-GAAP metric) was $(509,000)"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Revenue Increases to $13.6 Million -

- Net Income from Continuing Operations Increases by $1.2 Million to $1.5 Million and Adjusted EBITDA From Continuing Operations Increases by $0.9 Million to $2.3 Million -

- Continued Execution on Capital Allocation Priorities with Regional Developer Territory Buybacks and $3.8 Million in Stock Repurchases -

- Board of Directors Authorizes an Additional $5.0 Million for Stock Repurchases -

SCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, today reported financial results for the third quarter ended September 30, 2026. The following figures represent continuing operations unless otherwise stated. The Company also updated its full year 2026 guidance (see details below).

Third Quarter 2026 Financial Highlights

• Revenues grew to $13.6 million, up 1% compared to the third quarter of 2025.
• System-wide sales¹ were $123.3 million, a 3.1% decrease compared to the third quarter of 2025.
• Reported comp sales² of (1.9)%, compared to (2.8)% in the second quarter of 2026.
• Net loss from consolidated operations was $117,000, compared to net income from consolidated operations of $855,000 in the third quarter of 2025. Net income from continuing operations was $1.5 million, compared to net income from continuing operations of $290,000 in the third quarter of 2025.
• Adjusted EBITDA (a non-GAAP metric) from consolidated operations was $3.3 million, in line with $3.3 million in the third quarter of 2025. Adjusted EBITDA from continuing operations was $2.3 million, compared to $1.4 million in the third quarter of 2025.
• Cash flow used in operating activities was $128,000, compared to cash provided by operating activities of $1.8 million in the third quarter of 2025, and free cash flow (a non-GAAP metric) was $(509,000), compared to $1.5 million in the third quarter of 2025.
• Repurchased 461,000 shares for total consideration of approximately $3.8 million at an average of $8.30 per share during the third quarter.

Third Quarter 2026 and Recent Operating Highlights

• On October 1, 2026, the Company reacquired the regional developer (“RD”) rights for Texas, a region consisting of 141 franchised clinics, for total cash consideration of $8.0 million due at closing and up to $2.0 million in potential additional consideration payments if certain gross sales metrics are met or exceeded in the Texas region during the two annual periods following the closing.
  • Year to date in 2026, the Company has reacquired the RD rights to five territories, including Texas, consisting of 189 franchised clinics. These efforts will lead to the realization of approximately $3.0 million in reduced RD royalties on an annualized basis, with approximately one-third of this benefit being offset by internal costs to manage these territories.
• Total clinic count was 930 at September 30, 2026.
  • Opened four clinics, closed 15 clinics, and refranchised 26 clinics during the quarter, for a total of 915 franchised clinics and 15 company-owned or managed clinics at September 30, 2026.

^{1 System-wide sales include revenues at all clinics, whether operated or managed by the Company or by franchisees. While franchised sales are not recorded as revenues by the Company, management believes the information is important in understanding the Company’s financial performance because these revenues are the basis on which the Company calculates and records royalty fees and are indicative of the financial health of the franchisee base.}

^{2 Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.}

“Our third quarter results reflect growth in our active membership count as well as in the lifetime value per active member,” said President and Chief Executive Officer of The Joint Corp., Sanjiv Razdan. “By leaning into our value proposition, especially with our newer flexible membership options, we are driving more members to stay with us longer. Primarily reflecting the ongoing macroeconomic challenges, growth in these metrics is partially offset by lower average patient spend per month and fewer new patients, which is continuing to impact our comps. We believe our ability to grow our active membership count and our stronger new clinic performance is strengthening our foundation for future growth.

“Our success with our clinic refranchising efforts has positioned The Joint as a pure-play franchisor model, which, combined with RD territory buybacks already completed this year, is helping to drive margin improvement, profitability and cash flow. With our strong balance sheet and improving cash generation from continuing operations, we have the financial flexibility to continue to execute simultaneously on our growth strategies, RD territory buybacks and continued stock repurchase capital allocation priorities. Our additional $5 million stock repurchase authorization reflects our confidence that our asset-light franchise model and initiatives to reignite growth will help create long-term value for our stockholders.”

Continued Execution on Stock Repurchase Program

The Company’s initiative to refranchise previously company-owned or managed clinics to drive higher cash flows derived from an asset-light franchise model began in 2023, opening a pathway for the Company to begin executing on its first stock repurchase program. Since June 3, 2025, the Company has repurchased 1,975,352 shares for total consideration of $17 million.

During the third quarter of 2026, the Company repurchased approximately 461,000 shares for total consideration of approximately $3.8 million, at an average price of $8.30 per share. As of September 30, 2026, the Company had exhausted the full $12 million of the latest authorization for repurchasing shares.

On November 3, 2026, the Company’s Board of Directors authorized an additional $5 million for stock repurchases. Repurchases under this program may be made from time to time in open market transactions, privately negotiated transactions, or by other means in accordance with applicable securities laws and are subject to market conditions and other factors. The timing, frequency and amount of any repurchases will be determined by the Company’s management and Board of Directors. The stock repurchase program does not obligate the Company to acquire any particular amount of common stock.

Update on Refranchising Efforts

The Company has substantially completed the refranchising initiative under its Joint 2.0 strategy through previously announced clinic sale bundles:

• Southern California Bundle: Forty of the 45 clinics have been refranchised to date.
• Northern California Bundle: All four of these clinics have been refranchised to date.
• Southeast Bundle: Ten of the 20 clinics have been refranchised to date.

As a result of these refranchising efforts, The Company now operates as a capital-light, pure-play franchisor, allowing management to concentrate on driving growth through franchise system support, new patient acquisition, and long-term network development.

Financial Results for Third Quarter Ended September 30, 2026 Compared to September 30, 2025

Revenue totaled $13.6 million in the third quarter of 2026, compared to $13.4 million in the third quarter of 2025, reflecting the Company's continued transition to a pure-play franchisor revenue model. Cost of revenues was $2.4 million, down 10% compared to the prior-year period, primarily due to lower RD royalty costs as the Company continues to reacquire RD territories.

Selling and marketing expenses were $2.7 million, a decrease of 4% compared to the third quarter of 2025, primarily due to lower system-wide sales. Depreciation and amortization expenses were $262,000. General and administrative expenses decreased 6% to $6.9 million compared to $7.3 million in the third quarter of 2025, underscoring ongoing operating discipline within the leaner post-refranchising structure.

Consolidated net loss was $117,000, compared to a consolidated net income of $855,000 in the prior-year period. Net income from continuing operations was $1.5 million, compared to $290,000 in the third quarter of 2025. Consolidated EPS was $(0.01) per share, compared to $0.06 per diluted share in the third quarter of 2025.

Adjusted EBITDA from consolidated operations was $3.3 million, in line with $3.3 million in the third quarter of 2025. Adjusted EBITDA from continuing operations was $2.3 million, compared to $1.4 million in the prior-year period.

Balance Sheet

Unrestricted cash was $18.3 million at September 30, 2026, compared to $22.2 million at June 30, 2026. The Company maintains a currently undrawn line of credit with JPMorgan Chase Bank, which provides immediate access to $20 million through August 2029.

Financial Results for Nine Months Ended September 30, 2026 Compared to September 30, 2025

Revenue was $43.6 million in the first nine months of 2026, up 10% compared to $39.7 million in the same period in 2025. Consolidated net income was $1.8 million, compared to $1.9 million in the nine months ended September 30, 2025. Net income from continuing operations was $2.3 million, compared to a net loss from continuing operations of $1.2 million in the nine months ended September 30, 2025. Consolidated EPS was $0.13 per diluted share, compared to $0.12 per diluted share in the prior-year period.

Adjusted EBITDA from consolidated operations increased to $9.9 million and Adjusted EBITDA from continuing operations increased to $5.9 million, compared to Adjusted EBITDA from consolidated operations of $9.4 million and Adjusted EBITDA from continuing operations of $1.5 million in the nine months ended September 30, 2025.

2026 Guidance

Reflecting continued macroeconomic pressures on consumer spending and the reported financial results for the first nine months of 2026, the Company today updated its 2026 full year financial guidance provided on August 6, 2026, as follows:

• System-wide sales are now expected to be between $508 million and $512 million as compared to the prior range of $519 million to $552 million.
• System-wide comp sales for clinics open 13 months or more are now expected to be in the range of (3.5)% to (2.5)% as compared to the prior range of (3)% to 3%.
• Consolidated Adjusted EBITDA is unchanged and is expected to be in the range of $12.5 million to $13.5 million.

The Company continues to work with franchise owners to optimize the performance of the existing franchised clinic base. This will include closing underperforming clinics this year, which will result in the overall clinic count at 2026 year-end being approximately 50 clinics lower than 2025 year-end.

Conference Call

The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, November 5, 2026, after the market close. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing (833) 630-0823 or (412) 317-1831 and asking to be joined into the “The Joint” call approximately 15 minutes prior to the start time. The live webcast of the call, including the accompanying slide presentation, can be accessed directly here.

A replay of the webcast will be archived on the Company’s investor relations website for approximately one year. An audio replay of the conference call will be available through Thursday, November 12, 2026, and can be accessed by dialing (855) 669-9658 or (412) 317-0088 and entering conference ID 4727728.

About The Joint Corp. (NASDAQ: JYNT)

The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The Company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale and with over 925 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times’ annual “Top 400” and “Fast & Serious” list of smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and it is regularly ranked on the publication’s “Franchise 500®,” “Fastest-Growing Franchises,” and “Best of the Best” lists, as well as its “Top Franchise for Veterans” and “Top Brands for Multi-Unit Owners” rankings. SUCCESS® named the Company one of the “Top 50 Franchises”. The Joint Chiropractic is an innovative force where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Commonly Discussed Performance Metrics

This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the Company or by franchisees. While franchised sales are not recorded as revenues by the Company, management believes the information is important in understanding the Company’s financial performance because these sales are the basis on which the Company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

Non-GAAP Financial Information

This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company’s underlying operating performance and operating trends. Free cash flow is presented as a supplemental measure of liquidity. Reconciliation of historical net income/(loss) to EBITDA and Adjusted EBITDA and reconciliation of operating activities cash flows to free cash flow is presented in the tables below. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired RD rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, and litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business). The Company defines free cash flow as net cash provided by (used in) operating activities less capital expenditures. EBITDA, Adjusted EBITDA and free cash flow do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States (“GAAP”). While EBITDA and Adjusted EBITDA are used as measures of financial performance and free cash flow is used as a measure of liquidity, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA, Adjusted EBITDA and free cash flow should be reviewed in conjunction with the Company’s financial statements filed with the Securities and Exchange Commission (the “SEC”). Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located at the end of this release. This release includes forward-looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the Company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

Forward-Looking Statements

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as "anticipates," "believes," "continues," "estimates," "expects," "goal," "objective," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward-looking statements made in this press release include, among others, our belief that our efforts to reacquire the RD rights to five territories will lead to the realization of approximately $3.0 million in reduced RD royalties on an annualized basis, with approximately one-third of this benefit being offset by internal costs to manage these territories; our belief that our third quarter results reflect growth in our active membership count as well as in the LTV per active member; our belief that by leaning into our value proposition, including with our newer flexible membership options, we are driving more members to stay with us longer; our belief that, primarily reflecting the ongoing macroeconomic challenges, growth in these metrics is partially offset by lower average patient spend per month and fewer new patients, which is continuing to impact our comps; our belief that our ability to grow our active membership count, combined with improving patient conversion and retention rates as well as our stronger new clinic performance, is [strengthening/establishing] our foundation for future growth; our belief that our success with our clinic refranchising efforts has positioned The Joint with a pure-play franchisor model, which, combined with RD territory buybacks already completed this year, is helping to drive margin improvement, profitability and growing cash flow; our belief that, with our strong balance sheet and improving cash generation from continuing operations, we have the financial flexibility to continue to execute simultaneously on our growth strategies, RD territory buybacks and continued share repurchase capital allocation priorities; our belief that our additional $5 million share repurchase authorization reflects our confidence that our asset-light franchise model and initiatives to reignite growth will help create long-term value for our stockholders; and our updated 2026 guidance for system-wide sales, system-wide comp sales, consolidated Adjusted EBITDA, existing franchised clinic closures, and overall clinic count. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs and increased gas prices, may lead to reduced discretionary spending, all of which may negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 13, 2026 and subsequent filings with the SEC. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Investor Contact:
Richard Land, Alliance Advisors IR, thejointinvestor@allianceadvisors.com (212) 838-3777

– Financial Tables Follow – 

THE JOINT CORP. CONDENSED CONSOLIDATED BALANCE SHEETS
	September 30, 2026				December 31, 2025
ASSETS	(unaudited)
Current assets:
Cash and cash equivalents	$	18,299,059			$	23,601,810
Restricted cash		569,643				700,058
Accounts receivable, net		2,475,757				2,849,864
Notes receivable		109,833				—
Deferred franchise and regional development costs, current portion		880,954				945,933
Prepaid expenses and other current assets		3,049,327				1,744,556
Discontinued operations current assets ($1.0 million attributable to VIEs)		7,486,845				22,246,318
Total current assets		32,871,418				52,088,539
Property and equipment, net		2,800,073				3,159,226
Operating lease right-of-use asset		1,395,838				1,572,173
Notes receivable, net of current portion		325,374				—
Deferred franchise and regional development costs, net of current portion		3,043,629				3,827,129
Deposits and other assets		262,308				319,460
Total assets	$	40,698,640			$	60,966,527
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	749,976			$	1,588,665
Accrued expenses		1,633,471				1,501,838
Co-op funds liability		569,643				700,058
Payroll liabilities		2,984,053				4,055,752
Operating lease liability, current portion		349,447				194,179
Deferred franchise fee revenue, current portion		2,495,505				2,519,018
Upfront regional developer fees, current portion		164,564				277,394
Other current liabilities		616,877				611,231
Discontinued operations current liabilities ($1.2 million and $6.1 million attributable to VIEs, respectively)		7,184,973				21,368,446
Total current liabilities		16,748,509				32,816,581
Operating lease liability, net of current portion		1,605,077				1,815,527
Deferred franchise fee revenue, net of current portion		9,896,113				10,899,271
Upfront regional developer fees, net of current portion		181,788				355,556
Total liabilities		28,431,487				45,886,935
Commitments and contingencies
Stockholders' equity:
Series A preferred stock, $0.001 par value; 50,000 shares authorized, zero shares issued and outstanding, respectively		—				—
Common stock, $0.001 par value; 20,000,000 shares authorized, 15,719,285 shares issued and 13,701,928 shares outstanding and 15,471,715 shares issued and 14,142,626 shares outstanding, respectively		15,719				15,471
Additional paid-in capital		53,102,139				52,026,407
Treasury stock 2,017,357 shares and 1,329,089 shares, at cost, respectively		(17,915,296	)			(12,192,081	)
Accumulated deficit		(22,960,409	)			(24,795,205	)
Total The Joint Corp. stockholders' equity		12,242,153				15,054,592
Non-controlling interest		25,000				25,000
Total equity		12,267,153				15,079,592
Total liabilities and stockholders' equity	$	40,698,640			$	60,966,527

THE JOINT CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
		Three Months Ended September 30,							Nine Months Ended September 30,
			2026				2025			2026				2025
Revenues:
Royalty fees		$	8,254,366			$	8,106,915		$	24,614,204			$	24,311,022
Franchise fees			893,882				964,796			2,789,537				2,561,415
Advertising fund revenue			2,391,339				2,344,833			9,754,259				6,985,030
Software fees			1,578,567				1,545,331			4,660,799				4,488,959
Other revenues			433,554				418,810			1,735,056				1,382,119
Total revenues			13,551,708				13,380,685			43,553,855				39,728,545
Cost of revenues:
Franchise and regional developer cost of revenues			1,980,494				2,232,419			6,320,591				7,134,267
IT cost of revenues			423,074				428,815			1,282,882				1,271,700
Total cost of revenues			2,403,568				2,661,234			7,603,473				8,405,967
Selling and marketing expenses			2,704,777				2,816,081			11,307,832				9,805,075
Depreciation and amortization			261,779				446,736			1,081,333				1,210,961
General and administrative expenses			6,851,612				7,295,719			21,492,814				21,955,915
Total selling, general and administrative expenses			9,818,168				10,558,536			33,881,979				32,971,951
Net loss on disposition or impairment			—				—			233,420				6,413
Income (loss) from continuing operations			1,329,972				160,915			1,834,983				(1,655,786	)
Other income, net			136,417				139,801			503,090				485,640
Income (loss) before income tax expense			1,466,389				300,716			2,338,073				(1,170,146	)
Income tax expense			10,069				10,346			30,289				35,140
Net income (loss) from continuing operations			1,456,320				290,370			2,307,784				(1,205,286	)
Discontinued operations:
(Loss) income from discontinued operations before income tax expense			(1,593,877	)			664,269			(313,375	)			3,424,697
Income tax (benefit) expense from discontinued operations			(20,197	)			99,630			159,613				303,243
Net (loss) income from discontinued operations			(1,573,680	)			564,639			(472,988	)			3,121,454
Net (loss) income		$	(117,360	)		$	855,009		$	1,834,796			$	1,916,168
Net income (loss) from continuing operations per common share:
Basic		$	0.10			$	0.02		$	0.16			$	(0.08	)
Diluted		$	0.10			$	0.02		$	0.16			$	(0.08	)
Net (loss) income from discontinued operations per common share:
Basic		$	(0.11	)		$	0.04		$	(0.03	)		$	0.20
Diluted		$	(0.11	)		$	0.04		$	(0.03	)		$	0.20
Net (loss) income per common share:
Basic		$	(0.01	)		$	0.06		$	0.13			$	0.12
Diluted		$	(0.01	)		$	0.06		$	0.13			$	0.12
Basic weighted average shares			14,030,130				15,344,844			14,151,503				15,281,775
Diluted weighted average shares			14,032,055				15,398,594			14,154,157				15,348,944

THE JOINT CORP. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
		Nine Months Ended September 30,
			2026				2025
Cash flows from operating activities:
Net income		$	1,834,796			$	1,916,168
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			1,090,914				1,270,776
Net loss on disposition or impairment			3,512,246				3,752,862
Net franchise fees recognized upon termination of franchise agreements			(417,315	)			(257,797	)
Provision for credit losses			330,621				149,719
Stock-based compensation expense			1,038,752				971,138
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable			288,722				1,464,026
Prepaid expenses and other current assets			(794,596	)			(424,897	)
Deferred franchise costs			621,762				382,986
Deposits and other assets			164,494				(19,280	)
Accounts payable			(897,087	)			(649,903	)
Accrued expenses			(1,227,636	)			(3,475,804	)
Payroll liabilities			(1,902,615	)			(925,440	)
Operating leases			(2,166,672	)			(3,843,956	)
Deferred revenue			(1,397,169	)			(1,643,696	)
Upfront regional developer fees			(286,597	)			(215,524	)
Other liabilities			794,968				489,649
Net cash provided by (used in) operating activities			587,588				(1,058,973	)
Cash flows from investing activities:
Proceeds from sale of clinics			1,426,000				7,778,287
Purchase of property and equipment			(871,031	)			(1,154,385	)
Net cash provided by investing activities			554,969				6,623,902
Cash flows from financing activities:
Payments of finance lease obligation			—				(4,354	)
Purchases of treasury stock under employee stock plans			(76,818	)			(8,440	)
Purchases of common stock under stock repurchase programs			(5,646,397	)			(2,288,994	)
Proceeds from exercise of stock options			37,228				1,453,558
Net cash used in financing activities			(5,685,987	)			(848,230	)
(Decrease) increase in cash, cash equivalents and restricted cash			(4,543,430	)			4,716,699
Cash, cash equivalents and restricted cash, beginning of period			24,301,868				25,996,436
Cash, cash equivalents and restricted cash, end of period		$	19,758,438			$	30,713,135
Reconciliation of cash, cash equivalents and restricted cash:		September 30, 2026				September 30, 2025
Cash and cash equivalents		$	18,299,059			$	29,699,953
Restricted cash			1,459,379				1,013,182
Cash, cash equivalents and restricted cash, end of period		$	19,758,438			$	30,713,135

THE JOINT CORP. CONSOLIDATED RECONCILIATION FROM GAAP TO NON-GAAP (unaudited)
	Three Months Ended September 30,
		2026												2025
	From Continuing Operations				From Discontinued Operations				Net Operations				From Continuing Operations				From Discontinued Operations			Net Operations
Non-GAAP Financial Data:
Net income (loss)	$	1,456,320			$	(1,573,680	)		$	(117,360	)		$	290,370			$	564,639		$	855,009
Net interest income		(136,417	)			—				(136,417	)			(253,277	)			—			(253,277	)
Depreciation and amortization expense		261,779				134				261,913				446,736				16,310			463,046
Income tax expense (benefit)		10,069				(20,197	)			(10,128	)			10,346				99,630			109,976
EBITDA		1,591,751				(1,593,743	)			(1,992	)			494,175				680,579			1,174,754
Stock-based compensation expense		335,572				—				335,572				346,209				—			346,209
Net loss on disposition or impairment		—				2,084,596				2,084,596				—				860,598			860,598
Costs related to restatement filings		—				—				—				113,477				—			113,477
Restructuring costs		192,156				109,492				301,648				355,042				102,024			457,066
Litigation expenses		148,480				401,943				550,423				100,000				250,000			350,000
Adjusted EBITDA	$	2,267,959			$	1,002,288			$	3,270,247			$	1,408,903			$	1,893,201		$	3,302,104

	Nine Months Ended September 30,
		2026												2025
	From Continuing Operations				From Discontinued Operations				Net Operations				From Continuing Operations				From Discontinued Operations			Net Operations
Non-GAAP Financial Data:
Net income (loss)	$	2,307,784			$	(472,988	)		$	1,834,796			$	(1,205,286	)		$	3,121,454		$	1,916,168
Net interest (income) expense		(504,605	)			—				(504,605	)			(599,116	)			239			(598,877	)
Depreciation and amortization expense		1,081,333				9,581				1,090,914				1,210,961				59,815			1,270,776
Income tax expense		30,289				159,613				189,902				35,140				303,243			338,383
EBITDA		2,914,801				(303,794	)			2,611,007				(558,301	)			3,484,751			2,926,450
Stock-based compensation expense		1,038,752				—				1,038,752				971,138				—			971,138
Acquisition-related expenses		332,005				—				332,005				—				—			—
Net loss on disposition or impairment		233,420				3,278,826				3,512,246				6,413				3,746,449			3,752,862
Costs related to restatement filings		—				—				—				113,477				—			113,477
Restructuring costs		932,493				166,275				1,098,768				910,619				371,739			1,282,358
Litigation expenses		495,174				823,719				1,318,893				100,000				250,000			350,000
Adjusted EBITDA	$	5,946,645			$	3,965,026			$	9,911,671			$	1,543,346			$	7,852,939		$	9,396,285

THE JOINT CORP. RECONCILIATION OF OPERATING ACTIVITIES CASH FLOWS TO FREE CASH FLOW(1) (unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Cash flows (used in) provided by operating activities		$	(128,462	)		$	1,773,032			$	587,588			$	(1,058,973	)
Purchase of property and equipment			(380,173	)			(317,840	)			(871,031	)			(1,154,385	)
Free cash flow		$	(508,635	)		$	1,455,192			$	(283,443	)		$	(2,213,358	)
(1)          Free cash flow represents cash flows (used in) provided by operating activities less capital expenditures.

---

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were The Joint's third-quarter 2026 earnings results?

The Joint reported $13.6 million revenue and a $117,000 consolidated net loss. Revenue increased 1% year over year, while consolidated results compared with $855,000 net income a year earlier. Continuing-operations net income rose to $1.5 million from $290,000.

What is The Joint's updated 2026 financial guidance?

The Joint expects $508 million–$512 million in system-wide sales and comparable-sales declines of 3.5%–2.5%. The prior ranges were $519 million–$552 million and negative 3%–positive 3%, respectively. Expected consolidated adjusted EBITDA remains $12.5 million–$13.5 million.

What triggers The Joint's additional payments for the Texas regional developer rights?

Up to $2.0 million in additional consideration is payable if specified Texas gross sales metrics are met or exceeded during the two annual periods following closing.

How far has The Joint progressed with its clinic sale bundles?

The Joint has refranchised 40 of 45 Southern California clinics, all four Northern California clinics, and 10 of 20 Southeast clinics. The company describes its refranchising initiative as substantially completed.